Australia's Therapeutic Goods Administration has scheduled BPC-157 as Schedule 9 (Prohibited Substance) effective July 1, 2026
This helps make sure your treatment is working well
Risk factors include occupations requiring prolonged standing, being overweight, having flat feet or high arches, tight calf muscles, and sudden increases in physical activity
Rarely, rashes or skin reactions have been reported
Published preclinical studies use it as a chemical research tool in cell and animal models investigating ERR signaling, mitochondrial function, cellular respiration, oxidative metabolism, and exercise-response pathways
What youll actually see: Weeks 4-8 : Reduced hair shedding, improved hair shaft thickness in existing hairs, healthier scalp condition Weeks 8-16 : New hair growth in areas of miniaturization (particularly crown and hairline in androgenic alopecia patterns), visible increase in hair density Months 4-6+ : Continued thickening and coverage improvement, particularly when combined with other optimization strategies Clinical data shows GHK-Cu is particularly effective for androgenic alopecia (male pattern baldness) and telogen effluvium (stress-related shedding), but expectations must be calibrated to your starting condition